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Abstract 
Purpose: Nuclear factor-kappa B (NF- signalling has been shown to regulate properties of 
breast cancer stem cells. However, the specific contribution of the non-canonical NF-
pathway, components of which are elevated in aggressive breast cancer has not been addressed.  
Methods: Through shRNA silencing of the Nfkb2 gene, the role of p100/p52 in 4T1 and 
N202.1A cell lines were assessed by NF-  reporter, invasion, tumoursphere and orthotopic 
transplantation assays. The processing of p100 into p52 was also inhibited with a p97 ATPase 
inhibitor, NMS-873, and its effects on tumoursphere formation was assessed. 
Results: K nockdown of Nfkb2 led to opposing changes in NF- -
(CSC) activity and tumourigenicity in vivo. Conversely, depletion of Nfkb2 in N202.1a cells 
decreased NF- urigenicity in vivo. By selectively over-
expressing the p52 subunit in Nfkb2 depleted cells, we found that the increased malignancy in 
4T1 cells could not be reverted in the presence of p52 whereas the decreased tumourigenicity of 
N202.1a cells could be rescued by p52. These results indicate that p100 and its subunit p52 have 
opposing effects on breast CSC activity. Accordingly, inhibition of an upstream regulator of 
p100 processing was effective in reducing tumoursphere formation of  N202.1A and SK BR3 
(ErbB2 
HIGH
) cells without aggravating that of 4T1 and MDA-MB-231 (ErbB2
LOJ
) cells.  
Conclusion: These findings indicate that inhibiting the processing of p100 may be a potential 
therapeutic strategy to suppress CSC activity in a subset of breast tumours.   
K eywords: breast cancer, Nfkb2, NF-K appaB, cancer stem cell, ErbB2, p97 ATPase 
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Introduction 
Even though breast cancer predominantly affects women, it is the second most common 
form of cancer globally L1-4]. Significant advances have led to improved survival rates but the 
reality is that breast cancer is a heterogeneous disease which comprises of varying subtypes L5, 
6]. Jhile prognoses have improved for certain subtypes, some remain less adequate. This is 
mainly due to therapeutic resistance, metastasis and tumour relapse, which can be attributed at 
least in part to a subpopulation of cells with increased tumor initiating potential, termed cancer 
stem cells. 
The existence of cancer stem cells (CSCs) were first shown in hematopoietic 
malignancies L7, 8] and more recently, the presence of CSCs in breast tumours represented the 
first indication of CSCs in solid tumours L9]. The CSC hypothesis states that cells within a 
tumour are not equal in their tumorigenic potential. Evidence suggests that within this hierarchy, 
it is the CSCs that fuel the growth of a tumour resulting in therapeutic resistance, disease relapse 
and the seeding of metastases in a range of cancer subtypes L10, 11].  CSCs have been shown to 
utilize and depend on distinct signalling pathways from non-CSCs and this suggests a possibility 
for specific therapeutic targeting to eradicate CSCs L12-14].    
One such candidate pathway involves NF- dependent transcription. NF- signalling 
has been shown to promote breast CSC properties L35] and to result in EMT and metastasis in 
animal models of breast cancer L28-30]. The NF-
initially identified as regulators of the immune system. There are five different subunits which 
can form homo- or heterodimers to regulate the expression of genes. Namely, these are RelA  
(p65), RelB, c-rel, p50 and p52. A ll of these subunits have a conserved Rel homology domain 
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which facilitates DNA binding and dimerization. However, p50 and p52 differ from the Rel 
proteins in two ways. Firstly, they lack trans-activating domains which are important for 
initiating transcription. Secondly, p50 and p52 are translated as precursor proteins p105 and p100 
respectively. These precursor proteins are inhibitor of NF-
presence of ankyrin repeats at the C-terminus. These motifs are removed upon partial 
proteasomal processing into p50 or p52 
- proteins function by masking the nuclear 
localization signal of NF-  them in the cytoplasm. There are two main 
NF- namely, the canonical and alternative pathways. Transcriptional activity 
induced by canonical NF- -p50 dimers whereas the alternative 
pathway is dependent on RelB-p52 dimers. The alternative pathway, which is associated with 
constitutive NF- activity in normal and tumour cells is maintained through a signalling 
cascade involving NF-
phosphorylation and processing into p52. The loss of ankyrin domains from the C-terminus of 
p100 then allows translocation of RelB-p52 heterodimers into the nucleus  L15, 16]. P100 also 
actively shuttles between the nuclear and cytoplasm and plays an inhibitory role by sequestering 
other NF-  subunits in the nucleus L17, 18]. The processing of p100 into p52 has also been 
recently shown to depend on the ATPase activity of p97 and this presents a critical regulation 
point where the alternative pathway can be inhibited L19]. Taken together, the roles of the Nfkb2 
gene which encodes both the p100 inhibitory subunit and p52 transcription factor is likely to be 
complex and context dependent.   
As breast cancers are scrutinized further into more distinct subtypes L20], it is likely that 
more specific therapies will lead to more effective targeting of each particular subtype with less 
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side effects. The canonical NF- portant for tumorigenesis 
and CSC properties especially in estrogen receptor (ER) negative and ErbB2 driven tumours L21-
24], yet the alternative pathway is also known to play a key role in driving oncogenic pathways 
such as inducing cyclin D1 expression L25, 26]. Aberrant levels of alternative NF-  pathway 
components in human breast cancer tissue have been described L27, 28]. However, since p100 
and p52 are known to play opposing roles in the regulation of the alternative NF-
set out to determine whether certain breast cancers may respond differentially to silencing of the 
Nfkb2 gene, and whether this acts on breast CSC viability. Interestingly, we found that depletion 
of Nfkb2 has context dependent effects on 4T1 (ErbB2
low
) and N202.1A (ErbB2
high
) mammary 
cancer cell lines respectively. NF-  activity was found to be differentially affected in these cell 
lines upon Nfkb2 silencing and this led to corresponding phenotypes associated with cancer stem 
cell properties and activity. Jhile our results corroborate previous findings where Nfkb2-
mediated transcription was shown to be important for breast cancer stem cell activity L29], we 
provide evidence that selective targeting of p52 rather than upstream Nfkb2/p100 expression 
may have a more beneficial therapeutic potential in the in vivo setting. 
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Materials and Methods 
Reagents and antibodies 
Plasmid containing human p52 sequence was a kind gift from Professor Neil Perkins 
(Newcastle University). This HA-tagged p52 sequence was excised by X baI-PstI digestion and 
ligated into the cloning site of P305 lentiviral plasmid. (Dr. Riccardo Brambilla, Cardiff 
University). NF-
plasmid (Professor Ron Hay, University of St. Andrews) and pcDNA3.1-LacZ plasmid 
(Invitrogen) was used as control for transduction efficiency. Packaged lentiviral vectors encoding 
shRNA against Nfkb2 (NM_019408) or non-target (NT) (SHC002V ) control sequences were 
-actin (Abcam, Ab8227), Lamin 
A/C (CST 4777), p65 (CST 8243), p105/p50 (eBioscience 14-6732-81) and p100/p52 
(SantaCruz, SC-
experiments, CD29 (BD Biosciences, 562155), CD61 (eBioscience, 13-0611-81), CD44 
(Biolegend, 103007) and CD24 (Biolegend, 311106) antibodies were used. 
Cell culture 
4T1 cells L30] were obtained from Dr. Robin Anderson (University of Melbourne) and 
N202.1A cells L31] were a kind gift from Dr. Pier-Luigi Lollini (Sezione di Cancerologia, Italy). 
4T1 and SK BR3 cells were cultured in RPMI medium with 10% fetal bovine serum (FBS). 
N202.1A and MDA-MB-231 cells were cultured in DMEM medium that is supplemented with 
FBS at 10%. All media were also supplemented with 2mM L-glutamine and 50units/ml 
penicillin-streptomycin. For generation of stable cell lines, cells transduced with respective 
lentivirus were then cultured in 4ug/ml puromycin for 4T1 cells and 1ug/ml puromycin for 
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N202.1a. For BAY  11-7082 (Cayman Chemical) and NMS-873 (Apexbio) experiments, 
mammary cancer cells were maintained with 1µ M BAY  11-7082 or NMS-873 throughout the 
time period of the assay.   
NF-  
Cells were seeded in clear bottom black well plates and transfected 24 hours later with 
NF- -LacZ as control for transfection efficiency using 
L ipofectamine 2000 (Invitrogen). After 48 hours, cells were lysed with Glo-lysis buffer 
(Promega). Luciferase and LacZ activity was measured after adding Bright-Glo (Promega) and 
Beta-
luminescence were measured using a Flurostar Optima plate reader (BMG Labtech).  
T ranswell migration assay 
Cells were dissociated into single cell suspension and seeded into each 24-well cell 
culture insert with 8um pores (BD Biosciences). Cells were seeded with respective medium 
containing 0.1% FBS at a density of 25,000 cells/chamber. Migration was stimulated by a serum 
gradient. After 24 hours, cells were fixed with ice cold 70% ethanol. Cells on the upper surface 
were then removed mechanically and the membranes were stained with haematoxylin and eosin 
for visualization. 
Mammosphere forming assay 
Cells were dissociated into single cell suspensions and re-suspended in mammosphere 
culture medium (MEBM, Lonza) supplemented with B27, 5mg/ml insulin, 20ng/ml Epidermal 
-mercapthoethanol. Cells were seeded 
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at a density of 500cells/well in ultra-low attachment 96-well plates (Corning) and incubated for 7 
days. Passaging was achieved by dissociating mammospheres into single cell suspensions and re-
plating under similar conditions. 
qRT -PCR  analysis 
Isolation of RNA from cells was carried out using the RNeasy Mini K it (Qiagen, Sussex, 
 cDNA was synthesized from RNA samples 
using RevertAID Premium Reverse Transcriptase (Fermentas). SY BR Green reagent 
(Invitrogen) was used in the reaction mastermix and thermal cycling was carried out with a Step 
One Plus Realtime PCR System (Applied Biosystems). Cycling conditions used for all reactions 
consisted of; initial denaturation for 10 minutes at 95
o
C, followed by 45 cycles of 95
o
C for 15 
seconds and 60
o
C for 1 minute. List of primers used are: GAPDH F-
CACAGTCAAGGCCGAGAATG, GAPDH R-TCTCGTGTTCACACCCATC, SNAIL F-
TGAGAAGCCATTCTCCTGCT, SNAIL R-CTTCACATCCGAGTGGGTTT, SLUG F-
TCTGCAGACCCACTCTGATG, SLUG R-AGCAGCCAGACTCCTCATGT, TJIST1 F-
CAGGCCGGAGACCTAGATGTCAT, TJIST1 R-TGCCCCACGCCCTGATTCTTG, 
TJIST2 F-CTTCTCCGTGTGGCGCAT, TJIST2 R-CCGCATCCAGTTCCGCAT, ZEB2 F-
CCGGGAGCTGTTTCTTCG, ZEB2 R-CGCAGGCTCGATCTGTGA, ECADHERIN F-
CAGATGATGATACCCGGGACAA, ECADHERIN R-GGAGCCACATCATTTCGAGTCA, 
NCADHERIN F-AGGACCCTTTCCTCAAGAGC, NCADHERIN R-
ATAATGAAGATGCCCGTTGG. CT values obtained were processed using  the 2
-
 relative 
quantification method L32]. 
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Jestern Blotting 
 Protein lysates were collected from cultured cells by lysing with RIPA buffer (150mM 
sodium chloride, 1% v/v Nonidet-P40, 0.1% w/v sodium dodecyl sulphate, 0.5% w/v sodium 
deoxycholate, 50mM Tris pH8) with the addition of complete mini protease inhibitor tablets 
(Roche) and phosphatase inhibitors (10mM sodium fluoride, 1mM sodium orthovanadate, 10mM 
sodium pyrophosphate). Proteins were then separated by SDS-PAGE and immune-blotted for 
detection of proteins.  
F low cytometry analysis 
Cells were reconstituted in single cell suspensions and incubated with antibodies for 20 
minutes at 4
0
C. Flow analysis was carried out on a BD FACSCanto cell analyzer. 
Orthotopic transplantation of mammary cancer cells and tumour measurements 
For transplantation experiments, BalbC and NOD/SCID-BalbC mice of six to eight 
weeks of age were obtained from Charles River Laboratories. Maintenance, breeding and 
scientific procedures involving animals were carried out according to the guidelines set by the 
U.K . Home Office Regulations Animals (Scientific Procedures) Act 1986. Orthotopic cell 
transplants were carried out on mice between 8-12 weeks of age. For 4T1 transplants, cells were 
dissociated into single cell suspension and 10,000 cells were injected into the abdominal 
mammary glands. For N202.1a transplants, 50,000 cells were injected into NOD/SCID-BalbC 
mice.   
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Statistical analyses  
Data are presented as means ±SEM. For statistical analyses, two- -test 
was used and the threshold for significance was p<0.05. For tumor growth curves, ANCOV A 
test was used to determine significance. 
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Results 
K nockdown of Nfkb2 led to elevated basal NF - ivity in 4T 1 cells but decreased basal 
NF- in N202.1a cells 
 Through the analysis of The Cancer Genome Atlas (TCGA) breast datasets, we found 
elevated expression of NFK B2 transcripts in invasive breast carcinomas relative to normal breast 
tissue (Fig. 1a). This suggests a role for NFK B2 dependent signalling in advanced breast cancer. 
Consequently, we went on to address the direct contribution of Nfkb2 to the tumourigenic 
properties of two invasive mammary cancer cell lines, N202.1A and 4T1, by shRNA 
knockdown. NF- B activity has previously been reported to be associated with ErbB2 levels in 
breast cancer L26,27], and so as expected, the N202.1A cell line which was derived from an 
ErbB2 (Neu) over-expressing mammary tumour had concomitantly elevated nuclear p65 levels 
determined by western blot analysis compared to the ErbB2
LOJ
 mammary cell line 4T1 (Figure 
1b). In contrast however, the relative levels of nuclear p100/p52 and the ratio of p52 to p100 was 
higher in 4T1 cells relative to N202.1A cells.  After silencing Nfkb2, the nuclear p52 to p100 
ratio, as well as the nuclear to cytoplasmic p52 ratio, were further increased in 4T1 cells but 
decreased in N202.1A cells (Fig. 1b-1d) while no significant changes in the levels of p105, p50 
or p65 were observed in both nuclear and cytoplasmic fractions upon Nfkb2 knockdown. These 
relative changes in p52/p100 correlated with basal NF- B activity as indicated by NF-
reporter assay (Fig 1e). The different outcomes in activation of NF-  in the cell lines examined 
could be due to varying levels of upstream signals which affect basal processing of p100 into 
p52. Irrespective of the underlying mechanism for this difference however, it is clear that 
perturbation of p100/p52 levels affect basal NF- B activity and this demonstrates the 
contribution of non-canonical NF- -
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these mammary tumour cell lines.  Given the presumptive role for NF- signalling in tumour 
growth and malignancy, we set out to evaluate whether the differential effects on NF-  activity 
mediated by Nfkb2 suppression affected cancer associated phenotypes in these cell lines. 
 
K nockdown of Nfkb2 exclusively increased the motility of 4T 1 cells and this increase 
correlated with induction of E MT  
Je therefore examined the effects of Nfkb2 knockdown on the proliferative potential of 
mammary cell lines. Despite the previously described association between p52, cyclin D1 and 
proliferation in transformed cells L25], we did not observe any effects on the growth rate of cells 
(Online Resources 1a-b). Je also assessed the consequences of Nfkb2 knockdown on the colony 
forming potential of these cell lines but no significant differences were observed in the number 
of colony forming units (Online Resources 1a-c).  A  characteristic of tumour progression to 
malignancy is the phenotypic transition of a sub-population of tumour cells to become more 
motile and invade surrounding tissues. Je addressed the role of p100/p52 in the regulation of 
these phenotypes in vitro through transwell migration assays. The loss of p100/p52 increased the 
motility of 4T1 cells but had no effect on N202.1A cells (Fig. 2a, Online Resource 2). Motility 
was unaffected in N202.1A cells despite decreases in NF- B activity (Fig. 1e), suggesting that 
the alternative NF- As the increase in 
motility of 4T1 cells correlated with an increase in basal NF- Nfkb2 was 
silenced (Fig. 1e), we wanted to address whether the increase in motility was dependent on NF-
ity. Treatment of 4T1 Nfkb2 kd cells with the NF- inhibitor BAY  11-7082 
substantially decreased the motility of these cells to a level that was lower than untreated non-
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target (NT) control (Fig. 2b). Correspondingly, treatment of 4T1 NT cells with BAY  11-7082 
also decreased motility to a level that was comparable to BAY  11-7082 treated 4T1 Nfkb2 kd 
cells (Fig. 2b). This implied that NF- was required not only for the enhanced 
motility induced by silencing Nfkb2 in 4T1 cells, but also the inherent motility of these cells. In 
order to further dissect whether the loss of either p100 or p52 was responsible for the increase in 
motility of 4T1 Nfkb2kd cells, we re-expressed p52 in these cells but this failed to rescue the 
increase in motility due to silencing of Nfkb2 (Fig. 2c). This suggested that it was the loss of 
p100 that was most likely responsible for the increase in motility of 4T1 Nfkb2kd cells.  
Since NF-
(EMT) and EMT can confer cancer cells with increased migratory properties L33], we were 
interested in determining whether 4T1 Nfkb2kd cells acquired an EMT phenotype. The transcript 
levels of the EMT-inducing transcription factor Zeb2 were increased 1.6 fold in 4T1 Nfkb2kd 
cells compared to controls (Fig. 2d). Accordingly, we observed a decrease in levels of E-
cadherin and an increase in levels of N-cadherin relative to NT controls, which is characteristic 
of the EMT process.  
  
T he changes in basal NF- Nfkb2 knockdown correlated with the 
changes in CSC properties of 4T 1 and N202.1a cells respectively 
The NF- breast CSC maintenance 
and proliferation L21, 22, 29]. In view of that, we wanted to determine whether p100/p52 had a 
role in governing such properties. Jhen we analyzed the levels of putative breast CSC (i.e. 
CD29
hi
CD61
+
 cells) L34], a significant increase in the proportion of CSCs was observed for 4T1 
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cells (Fig. 3a and 3b) and on the other hand, CSC numbers were decreased by more than two fold 
for N202.1A cells (Fig. 3a and 3c). These changes led us to address CSC phenotypes by 
employing tumoursphere formation assays in serial passage.  In serial passage there was a two 
fold increase in the proportion of tumourspheres when Nfkb2 was silenced in 4T1 cells (Fig. 4a) 
while in N202.1A cells, a significant decrease in tumourspheres was observed following 
downregulation of Nfkb2 (Fig. 4a). Consequently, we tested the dependence on NF-
of respective tumoursphere forming potentials for 4T1 and N202.1A cell lines through inhibition 
with BAY  11-7082. Notably, BAY  11-7082 treatment abolished the tumoursphere forming 
potentials of both cell lines to almost undetectable levels (Fig. 4b and 4c). This shows that the 
inherent tumoursphere forming potential of 4T1 and N202.1A cells upon Nfkb2 silencing are 
dependent on NF- signalling. Over-expression of p52 in 4T1 Nfkb2 kd did not rescue the 
increased tumoursphere forming potential relative to 4T1 NT cells (Fig. 4d) further suggesting a 
role for un-processed p100 in 4T1 cell tumourigenesis. However, overexpression of p52 could 
rescue the decrease in sphere forming efficiency of N202.1A Nfkb2 kd cells (Fig. 4e), 
demonstrating a role for p52 in positively regulating tumoursphere forming potential.  
 
Silencing of Nfkb2 had opposing effects on the tumorigenic potentials of 4T 1 and N202.1a 
cells respectively in vivo 
These changes in CSC marker expression and mammosphere forming potential implicate 
the involvement of p100/p52 in the regulation of tumour initiating properties. Furthermore in 
vitro experiments indicated that 4T1 cells exhibited more aggressive phenotypes when p100/p52 
was depleted. To confirm these findings in vivo 4T1 NT and Nfkb2 kd cells were transplanted 
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into the mammary fat pads of recipient mice.  4T1 Nfkb2 kd cells exhibited enhanced growth 
kinetics (Fig. 5a). A lthough 4T1 Nfkb2 kd tumours were growing relatively faster than 4T1 NT 
tumours, we did not observe any differences in the proliferation or the number of apoptotic cells 
between the two cohorts, as determined by K i67 and cleaved caspase-3 immuno-staining 
respectively (Fig. 5b-d). This correlated with our findings in vitro (Online Resource 1), 
suggesting that the difference in tumour growth may be due to increased numbers of tumour 
stem/progenitor cells within the 4T1 Nfkb2 kd population.  
Concordantly, the decrease in N202.1A CSC activity observed in vitro correlated with a 
decrease in rate of tumour growth of N202.1A xenografts lacking Nfkb2 (Fig. 5e). Similarly, we 
did not observe any significant difference in the rate of proliferation or apoptosis between the 
N202.1a tumor cohorts as indicated by K i-67 and cleaved caspase-3 staining (Fig. 5f-h).  It is 
possible therefore that the retardation in N202.1a Nfkb2 kd tumor growth was due to decreased 
stem/progenitor cells at the onset of transplant rather than a more general effect on proliferation 
or cell death.  
 
NMS-873 treatment reduced the sphere forming potential of N202.1A and SK BR3 cells 
 Based on the contrasting effects observed in 4T1 and N202.1A cells and the potential role 
for un-processed p100 in these responses, we speculated that inhibition of p100 processing might 
be a more viable therapeutic strategy to avoid the loss of p100 and reduce p52 levels 
concurrently. For that reason, we inhibited an upstream regulator of p100 processing, the 
p97/V CP ATPase L19], using NMS-873, a potent and selective inhibitor of this ATPase. In serial 
passage tumoursphere cultures, we observed a decrease in the sphere forming potential of 
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N202.1A cells after NMS-873 treatment (Fig. 6A), which is consistent with our observations of  
Nfkb2 silencing in this cell line (Fig. 4A). Importantly, although there is no decrease in the 
sphere forming potential of 4T1 cells in the presence of NMS-873 (Fig. 6A), these cells did not 
exhibit increased sphere forming potential, as observed in 4T1 Nfkb2 kd cells (Fig. 4A). These 
results also suggest that ErbB2
HIGH
 cells may be more sensitive to p97 inhibition. Je expanded 
these observations into two human breast cancer cell lines, MDA -MB-231 (ErbB2
LOJ
) and 
SK BR3 (ErbB2
HIGH
), and similarly, NMS-873 was only effective in reducing sphere formation in 
SK BR3 cells (Fig. 6B). Je also examined the expression of CSC markers, CD24 and CD44 
upon NMS-873 treatment in these cell lines. In MDA -MB-231 cells, no significant changes in 
the CD44
+
CD24
-
 or CD44
+
CD24
+
 populations were observed (Online resource 3). As for 
SK BR3 cells, a CD44
+
CD24
-
 CSC population is not observed in this cell line. However, an 
increase in the CD44
+
CD24
+
 population was apparent in NMS-873 treated SK BR3 cells along 
with a decrease in the CD44
-
CD24
+ 
population (Online Resource 3). Interestingly, when we 
analyzed the expression of p97/V CP mRNA levels from TCGA Breast Invasive Carcinoma 
samples using the cbioportal website (http://cbioportal.org) L35, 36], the levels of p97 transcript 
was highest in the Her2-enriched breast cancer subtype. Taken together, these findings suggest 
that inhibiting the processing of p100 may be effective to suppress CSC activity in Her2-
enriched breast tumours.   
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Discussion 
Through silencing of the Nfkb2 gene in mammary cancer cell lines, we have 
demonstrated that concomitant loss of the Nfkb2 gene products, p100 and p52, leads to context 
dependent effects on the tumorigenicity of these cells. In 4T1 cells, we observed increased NF-
B activity, induction of EMT, increased motility, CSC properties and tumorigenicity in vivo. 
Our results are in line with previous studies which have shown the regulation of malignant tumor 
characteristics and CSC properties by the NF- pathway L21, 33, 37, 38]. Je propose that the 
increase in NF- B activity after Nfkb2 silencing may be due to the loss of p100 which plays 
more prominent negative regulatory roles in this cell type, suppressing both the canonical and 
alternative NF- B pathways L28]. It is more likely that the consequences of p100 depletion in 
these cells are mediated through the canonical pathway because reconstitution with p52 did not 
rescue or aggravate the increased motility and CSC traits in our studies.  
On the other hand, we showed that the CSC properties and tumorigenicity of N202.1A  
cells were positively regulated by p52. Significant decreases in CSC properties were observed in 
these cells upon Nfkb2 knockdown and the sphere forming potential could be rescued by 
reconstitution of p52. These results coincide with a recently published study which implicated 
the role of the alternative NF-  pathway in the regulation of breast CSCs L29]. Furthermore, 
upstream activators of the alternative NF-  
shown to positively regulate breast CSCs L39, 40]. As our results suggest a regulatory role for 
-
fold, losing the inhibitory function of p100 along with increased p52 activity. It is also worth 
noting that in the study where NIK  was implicated in regulation of breast CSCs L39], 
examination of NIK  protein levels through immunohistochemistry revealed that NIK  expression 
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was significantly higher in the Her2
+
 subtype and there was a positive correlation between NIK  
MMTV -Neu model L40].  
It is possible that not all breast cancers will exhibit a dependence on the alternative NF-
pathwa alignancy. Hence, it will be important to identify specific 
subtypes of breast cancer which will benefit from inhibition of the alternative NF- pathway. 
At present, it is known that NF- activity in general is elevated in Her2-eniched and basal 
subtypes of breast cancer L41, 42] but specifically, the alternative NF- pathway has not been 
associated with a more defined subset of breast cancers. Our data along with studies on upstream 
regulators of the alternative NF- L39, 40] would indicate that the alternative NF-
pathway may have a more important role in Her2-enriched breast tumors. Je have also 
previously shown that Bcl3, a protein which can form complexes with p52 or p50 dimers to 
activate NF- B, specifically plays a role in metastasis of ErbB2 driven tumors L43]. It would be 
interesting to address whether activation of the alternative NF- B pathway is required for the 
tumor promoting properties of Bcl3.  
A lthough the stratification of breast tumors into molecular subtypes have improved 
therapeutic outcomes and assisted in administration of specific therapies, current designation of 
tumor subtypes are based on the bulk of the tumor. Based on the CSC concept, it is possible that 
multiple breast cancer subtypes (Basal + Luminal) may be present within a tumour L14, 44]. 
Jith regards to that, the expression of Her2 has been shown to enrich for a luminal cancer stem 
cell population L45, 46] and plasticity for this Her2
+
 CSC population has been documented, even 
in tumors classified as Her2
-
 L47]. Hence it would be interesting to address whether our findings 
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may apply to Her2
+
 CSC subpopulations in breast tumours which are not classified as the Her2 
enriched subtype. 
Importantly, the context dependent effects we observed in different mammary cancer cell 
lines would advocate against targeting the Nfkb2 gene at the genetic level. Accordingly, it would 
be more appropriate to inhibit the processing of p100 into p52. By employing this therapeutic 
strategy, p52 transcriptional activity can be repressed and concomitantly, p100 levels can be 
maintained at higher levels. Since it is possible that p100 can also sequester canonical NF- B 
subunits, targeting the processing of p100 could provide additional benefits. Je have shown that 
inhibition of p97 can be effective in limiting CSC activity in a specific subset of breast cancer 
cells but other potential drug candidates  and NIK . In 
addition, RANK L inhibitors such as denosumab are already being employed clinically L48] and 
may prove to be effective in ameliorating certain breast CSCs. 
It appears that after NMS-873 treatment, there was increased CD44 expression in CD24
+
 
SK BR3 cells (Online Resource 3) which was inversely associated with its sphere forming 
potential (Figure 6B). A lthough CD44 positivity is associated with BCSC phenotypes L9], it is 
possible that only the combined expression pattern of CD44
+
CD24
-
 enriches for BCSCs. 
Accordingly, previous studies of clinical samples have showed an association between CD44 
positivityL49-51] and good prognosis but this observations may be convoluted because of the 
existence of various CD44 isoforms. 
In summary, we have shown that the Nfkb2 gene products p100 and p52, through their 
roles in the NF- pathway, regulate breast CSC properties. Je found that p100 may have more 
significant negative regulatory effects in 4T1
ERBB2LOJ
 cells whereas p52 activation was more 
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dominant in N202.1A
ERBB2HIGH
 cells. This led to contrasting effects on CSC properties and 
tumourigenicity upon Nfkb2 silencing. The opposing roles of p100 and p52 in the regulation of 
breast CSCs gives credence to the inhibition of p100 processing into p52 as a potential strategy 
to target breast CSCs.  
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Figure legends 
F igure 1: Silencing of Nfkb2 alters the basal NF- . a Boxplot of 
NFK B2 gene expression in tissue samples from TCGA breast dataset acquired through 
Oncomine software and based upon data generated by the TCGA Research Network: 
http://cancergenome.nih.gov/. Horizontal bars indicate median values, box edges represent 75
th
 
and 25th percentile, error bars show 90th percentile and 10th percentile, points show outlier 
values. b Immunoblots of nuclear and cytoplasmic extracts from 4T1 and N202.1A cells 
showing levels of NF- c Quantification of the ratio of nuclear p52 to nuclear p100 
from three independent immunoblots of 4T1 and N202.1A cells. d Quantification of the ratio of 
nuclear p52 to cytoplasmic p52 from three independent immunoblots of 4T1 and N202.1A cells. 
e Bar chart showing relative light units (RLU) from NF-
transfected with NF-  luciferase reporter and pcDNA3.1:lacZ as transfection control. 48 hours 
after transfection, cell lysates were harvested and the ratio of luciferase to lacZ activity 
measured. Bar charts show basal NF-  activity plotted as relative light units (RLU) in the 
respective cell lines. Data points represent average of at least n=6 and error bars indicate 
standard error of the mean (SEM). * indicates p<0.05, ** indicates p<0.01 and *** indicates 
p<0.001. 
 
F igure 2: Silencing of Nfkb2 increases the motility of 4T1 cells and this increase is associated 
with EMT in these cells.  a 4T1 and N202.1a cell lines transduced with non target (NT) and 
shRNA against Nfkb2 were plated in Boyden trans-well migration chambers and migration was 
induced via a serum gradient. Bar charts show the relative number of cells migrated (normalized 
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to 4T1 NT). b 4T1 NT and 4T1 Nfkb2 kd cells were plated in Boyden trans-well migration 
chambers in the presence or absence of 1uM BAY  11-7082 and migration was induced via a 
serum gradient. Bar charts show the number of cells migrated. c 4T1 cells transduced with non 
target (NT) shRNA, shRNA against Nfkb2 and shRNA against Nfkb2 with p52 over-expression 
were plated in Boyden trans-well migration chambers and migration was induced by a serum 
gradient. Bar charts show number of cells migrated normalized against NT control. d qPCR 
analysis of transcripts from 4T1 NT and 4T1 Nfkb2 kd cells. Levels of EMT inducing 
transcription factors were quantified as relative levels of transcripts normalized against NT 
 points represent average of at least n=6 and error bars 
indicate standard error of the mean (SEM). * indicates p<0.05, where statistical significance 
relative to NT controls were determined by two-tailed t-test. 
 
F igure 3: Effects of silencing Nfkb2 on the proportion of putative CSCs in mammary cancer cell 
lines. a Bar chart showing the percentage of CD29+ CD61+ CSCs in 4T1 and N202.1A cell lines 
transduced with non target (NT) or shRNA against Nfkb2. Data points represent average of at 
least n=6 and error bars indicate standard error of the mean (SEM), *** indicates p<0.001, where 
statistical significance relative to NT controls were determined by two-tailed t-test. 
Representative dot plots showing percentage of CD29+ CD61+ CSCs in (b) 4T1 and (c) 
N202.1A cell lines transduced with non target (NT) or shRNA against Nfkb2. 
 
F igure 4: Effects of silencing Nfkb2 on the CSC properties of mammary cell lines. a 4T1 and 
N202.1A cell lines transduced with non target (NT) or shRNA against Nfkb2 were plated in non-
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adherent culture plates with mammosphere media. Bar charts show % mammosphere forming 
units (MFUs) in Passage 2 calculated as the number of spheres per cells seeded. (b) 4T1 and (c) 
N202.1a cell lines in the first passage (P1) with or without 1uM BAY  11-7082 were dissociated 
and re-seeded at an equal density (P2) under non-adherent culture conditions in mammosphere 
media. The number of spheres formed in the presence or absence of BAY  11-7082 respectively 
after 7 days were counted. (d) 4T1 and (e) N202.1a cells transduced with non target (NT) 
shRNA, shRNA against Nfkb2 and shRNA against Nfkb2 with p52 over-expression were plated 
in non-adherent culture plates with mammosphere media and the number of spheres formed after 
7 days in passage 2 was counted. Bar charts show the number of spheres formed. Data points 
represent average of at least n=6 and error bars indicate standard error of the mean (SEM). * 
indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, n.s. indicates not significant, where 
statistical significance relative to NT controls were determined by two-tailed t-test. 
 
F igure 5: Effects of silencing Nfkb2 on the tumorigenic potential of mammary cancer cells in 
vivo. a 10,000  4T1 NT or Nfkb2 kd cells were transplanted into the right mammary fat pads of 
Balb/C mice respectively. Line graphs show the tumour growth kinetics of respective cell lines. * 
indicates p<0.05, where statistical significance between growth curves was determined by 
ANCOV A test; F=8.370, p=0.018. b Representative images from 4T1 NT and Nfkb2 kd tumours 
immuno-labelled with antibodies against K i67 and cleaved caspase-3 respectively. Scale bar 
represents 100um. c Bar charts showing number of K i67 positive nuclei per 10x field of view. d 
Bar charts showing number of cleaved caspase-3 positive cells per 10x field of view. e 50,000  
N202.1A NT or Nfkb2 kd cells were transplanted into the right mammary fat pads of NOD/SCID 
mice respectively. The resulting tumours were measured and the growth kinetics plotted as line 
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graphs. Data points represent averages from n=5 animals per cohort and error bars represent 
standard error of the mean. * indicates p<0.05, where statistical significance between growth 
curves was determined by ANCOV A test; F=7.754, p=0.021. f Representative images from 
N202.1a NT and Nfkb2 kd tumours immuno-labelled with antibodies against K i67 and cleaved 
caspase-3 respectively. Scale bar represents 100um. g Bar charts showing number of K i67 
positive nuclei per 10x field of view. h Bar charts showing number of cleaved caspase-3 positive 
cells per 10x field of view. 
 
F igure 6: NMS-873 inhibits the sphere forming potential of ErbB2 high mammary cancer cells. 
a 4T1 and N202.1A cell lines transduced with non target (NT) or shRNA against Nfkb2 were 
plated in non-adherent culture plates with mammosphere media in the absence or presence of 
-873. Bar charts show sphere forming efficiency in Passage 2 calculated as the 
number of spheres per cells seeded. b Bar charts showing the sphere forming efficiency of 
MDA-MB- -873. Data points 
represent average of at least n=6 and error bars indicate standard error of the mean (SEM). ** 
indicates p<0.01, *** indicates p<0.001, where statistical significance relative to NT controls 
were determined by two-tailed t-test. c Box plots showing the levels of V CP/p97 mRNA levels 
in patients from the Breast Invasive Carcinoma TCGA cohort grouped according to PAM50 
subtypes. Data was obtained using the cbioportal website and based upon data generated by the 
TCGA Research Network: http://cancergenome.nih.gov/. Statistical significance was determine 
using ANOV A test; F=8.69, p<0.0001. 
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Online Resorce 1: Silencing of Nfkb2 does not affect the proliferation and colony forming 
potential of mammary cancer cell lines. a Immnoblot showing the levels of p100 and p52 in 4T1 
and N202.1A cells after transduction with Non-Target (NT) or Nfkb2 shRNA. Growth curves 
showing the number of cells over time for (b) 4T1 and (c) N202.1A cells. d Colony forming 
assay of 4T1 and N202.1A cells seeded in 6-well plates at a density of 1000 cells/well and 
quantified after 7 days. Data points represent average of at least n=6 and error bars indicate 
standard error of the mean (SEM). N.S. indicates a non significant difference, where statistical 
significance relative to NT controls were determined by two-tailed t-test.  
 
Online Resorce 2: Silencing of Nfkb2 with independent shRNAs in 4T1 cells. a Immunoblot 
showing levels of p100 and p52 after knockdown with non target, p52 sh43 or p52 sh44 in 4T1 
cells. b Bar chart showing number of migrated cells in a 10x field of view for Boyden chamber 
migration assays of 4T1 non target, p52 sh43 or p52 sh44 cells. c Bar chart showing number of 
spheres formed for mammosphere forming assays of 4T1 non target, p52 sh43 or p52 sh44 cells. 
 
Online Resorce 3: Effects of NMS-873 treatment on CSC marker expression in human breast 
cancer cell lines. a Representative dot plots showing expression of CD44+ and CD24+ in MDA -
MB- -873 for 48 hours under normal 
culture conditions and analyzed by flow cytometry. Bar charts showing the percentage of b 
CD44
+
CD24
-
, c CD44
+
CD24
+
, or d CD44
-
CD24
+
 populations. Data points represent average of 
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at least n=6 and error bars indicate standard error of the mean (SEM), ** indicates p<0.01, where 
statistical significance relative to vehicle controls were determined by two-tailed t-test.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65






